The Food and Drug Administration is set to approve the “female Viagra” this week.

The drug, fibanserin, would be the very first officially sanctioned drug prescribed for low female sex drive in the world, according to New Zealand Herald.

But the drug would not work like its male equivalent that targets the genitals. The female version would combat a low libido by targeting the pleasure center of a woman’s brain. During the trials for the drug, women who took the pill every day reported to have sex more frequently and also reported to enjoy it more.

But the positive results of trials has been set off its pedestal by safety fears. The manufacturer of the drug is Sprout Pharmaceuticals. They originally created the pill as an antidepressant which was linked to side effects including fainting, nausea, fatigue, drowsiness, insomnia and low blood pressure.

Other critics have also brought up the fact that low female libido is from both psychological and physical factors. Fibanserin has been rejected twice before already due to its side effects. But this time around the USDA is giving a green light to use the medication as a treatment for hypoactive sexual desire disorder (HSDD).

When the drug was approved, the committee said that the benefits outweighed the risks, which is usually how most drugs pass, knowing that there are definitely side effects, but could be more likely to be a benefit.

Officials are however taking their time in order to come up with a solid plan on how to address the safely concerns, before the medication is ready for distribution.

Once the drug is approved and in use in the U.S., Sprout Pharmaceuticals has said that they will then give the medication interest in the European market, but further licensing will be required in certain areas.

Cindy Whitehead, chief executive officer of Sprout Pharmaceuticals, said recently: “We are one step closer to bringing to market the first treatment option for the most common form of female sexual dysfunction.”